AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31230881
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose formulation of the EV71 vaccine
Trial: 31230881
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose formulation of the EV71 vaccine
Trial: 20229041
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of E. coli lipopolysaccharide (LPS) at a dosage of 0.3 ng/kg
Trial: 20229041
Drug: Intravenous injection
RxNorm normalized name: Meta Trace FDG, intravenous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of E. coli lipopolysaccharide (LPS)
Trial: 8778004
Drug: Anti-fetal lymphocyte
RxNorm normalized name: lymphocyte immune globulin, anti-thymocyte globulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-fetal lymphocyte cytotoxic antibodies (AFCA) detection using complement dependent microcytotoxicity assay
Trial: 3149202
Drug: Pirenzepine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (10 mg intravenous bolus followed by 2.5 mg/h continuous infusion)
Trial: 23782962
Drug: Flu-50 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flu-50 (0.5 ml)
Trial: 23782962
Drug: Flu-25 (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flu-25 (0.25 ml)
Trial: 23782962
Drug: Control vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control vaccine (Fluzone®; 0.25 ml)
Trial: 18695440
Drug: Eptifibatide and
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide and unfractionated heparin according to the ESPRIT protocol
Trial: 18695440
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and unfractionated heparin
Trial: 16109110
Drug: Acetaminophen (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (500 mg), Aspirin (500 mg), Caffeine (130 mg)
Trial: 9495394
Drug: Positive inotropic
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive inotropic drugs (PIDs) including amrinone, dobutamine, epinephrine, or dopamine (≥ 5 microg x kg[‐1] x min[‐1])
Trial: 9495394
Drug: Positive inotropic
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive inotropic drugs (PIDs)
Trial: 24559015
Drug: 200 mL
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mL of an oral nutritional supplement containing maltodextrine and whey protein, consumed 150 to 210 min before gastroscopy
Trial: 23098412
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg three times daily before and during ascent to 4928 m
Trial: 17986746
Drug: RBC‐AT (Ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC‐AT (Ranitidine Bismuth Citrate 400 mg, Amoxicillin 1000 mg, Tetracycline 500 mg)
Trial: 17986746
Drug: RBC‐AC (Ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC‐AC (Ranitidine Bismuth Citrate 400 mg, Amoxicillin 1000 mg, Clarithromycin 500 mg)
Trial: 17986746
Drug: RBC‐MT (Ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC‐MT (Ranitidine Bismuth Citrate 400 mg, Metronidazole 500 mg, Tetracycline 500 mg)
Trial: 9678816
Drug: Bismuth subnitrate
RxNorm normalized name: Bismuth subnitrate
DrugBank: Bismuth subnitrate (DB13209)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth subnitrate (300 mg q.d.s.), omeprazole (20 mg b.d.), and amoxycillin (500 mg q.d.s.) for 14 days
Trial: 9678816
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg b.d.) and amoxycillin (500 mg q.d.s.) for 14 days
Trial: 9678816
Drug: Bismuth subnitrate
RxNorm normalized name: Bismuth subnitrate
DrugBank: Bismuth subnitrate (DB13209)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bismuth subnitrate with dual oral therapy
Trial: 9678816
Drug: Dual oral
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual oral therapy alone
Trial: 31837559
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg once daily (OD) for 6 months, started on day 3 postoperatively
Trial: 31837559
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg OD
Trial: 24130350
Drug: HCLC followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCLC followed by SAP therapy (intensive group; N = 48)
Trial: 24130350
Drug: Usual-care group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual-care group treated with multiple daily injections or insulin pump therapy (N = 20)
Trial: 24130350
Drug: HCLC followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCLC followed by SAP therapy (intensive group)
Trial: 20955776
Drug: Citalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (10 mg twice a day for 5 days)
Trial: 16781295
Drug: Finasteride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (1 mg daily)
Trial: 1884747
Drug: Rythmodan L.A.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rythmodan L.A. 250 mg b.d.
Trial: 1884747
Drug: Dirytmin Durettes
RxNorm normalized name: CUVETTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dirytmin Durettes 300 mg b.d.
Trial: 6819898
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metoclopramide and lisuride
Trial: 29053808
Drug: Age-Related Eye
RxNorm normalized name: casein, Lactococcus lactis cultured, aged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc and an addition of 10 mg meso‐zeaxanthin; n = 60
Trial: 29053808
Drug: Age-Related Eye
RxNorm normalized name: casein, Lactococcus lactis cultured, aged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age-Related Eye Disease Study 2 formulation with a low dose [25 mg] of zinc; n = 61
Trial: 14747781
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no contraceptive steroid)
Trial: 12659397
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive (30 microgram ethinylestradiol and 150 microgram desogestrel)
Trial: 7472661
Drug: Low nitrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low nitrogen and low calcium diet (0.49 +/- 0.11 g protein/(kg.d), 429 +/- 190 mg calcium/d)
Trial: 7472661
Drug: Low nitrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low nitrogen and high calcium diet (0.44 +/- 0.08 g protein/(kg.d), 1643 +/- 171 mg calcium/d)
Trial: 7472661
Drug: High nitrogen
RxNorm normalized name: Isosource High Nitrogen Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High nitrogen and high calcium diet (2.71 +/- 0.75 g protein/(kg.d), 1589 +/- 633 mg calcium/d)
Trial: 7472661
Drug: Baseline dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline dietary intake (0.99 +/- 0.51 g protein/(kg.d), 589 +/- 152 mg calcium/d)
Trial: 6791396
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of 1.6 mg of nitroglycerin (Group I)
Trial: 27563883
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone Therapy (HT) - 1 mg/day of estradiol valerate plus 5 mg/10 day of medroxiprogesterone
Trial: 23917935
Drug: Placebo (gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (gel with the same color and consistency and toothbrushing)
Trial: 18276619
Drug: Anti-Xa levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Xa levels > 0.9 IU/mL
Trial: 14623061
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg estradiol plus 1 mg norethindrone acetate
Trial: 11003744
Drug: Platelet activating
RxNorm normalized name: Platelet activating factor
DrugBank: Platelet Activating Factor (DB02261)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet activating factor antagonist (low-dose 10 mg or high-dose 100 mg)
Trial: 1443350
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg/day for 10 days)
Trial: 6536515
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Midazolam and Diazepam)
Trial: 23650913
Drug: Prophylactic endoscopic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic endoscopic injection sclerotherapy (EIS)
Trial: 20507401
Drug: Ciprofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (250 mg) every 12 hours for 6 months
Trial: 10733017
Drug: Leuprorelin 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin 3.75 mg (n=33)
Trial: 10733017
Drug: Lynestrenol 5
RxNorm normalized name: lynestrenol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lynestrenol 5 mg (n=23)
Trial: 8817830
Drug: Plasmodium falciparum
RxNorm normalized name: Plasmodium falciparum Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmodium falciparum circumsporozoite protein vaccine
Trial: 1306086
Drug: Diapulse therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diapulse therapy (pulsed electromagnetic energy of 27.12 MHz frequency)
Trial: 27825007
Drug: Tailored dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored dose-dense chemotherapy (4 cycles of leukocyte nadir-based tailored and dose-dense epirubicin and cyclophosphamide every 2 weeks followed by 4 cycles of tailored dose-dense docetaxel every 2 weeks)
Trial: 27825007
Drug: Standard 3-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 3-weekly chemotherapy (3 cycles of fluorouracil and epirubicin-cyclophosphamide every 3 weeks followed by 3 cycles of docetaxel every 3 weeks)
Trial: 24423358
Drug: TSH-suppressive L-T4
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TSH-suppressive L-T4 doses
Trial: 24423358
Drug: Replacement L-T4
RxNorm normalized name: L-T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Replacement L-T4 doses
Trial: 20686332
Drug: Sulbactomax (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulbactomax (1.5 g)
Trial: 12426862
Drug: Alfuzosin, doxazosin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin, doxazosin, tamsulosin, terazosin (α1‐adrenoceptor antagonists)
Trial: 12426862
Drug: Lower dosing
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dosing regimen of α1‐adrenoceptor antagonists
Trial: 11015162
Drug: Azithromycin, 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin, 1200 mg once weekly (n = 321)
Trial: 1360557
Drug: Aspirin 75
RxNorm normalized name: aspirin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 75 mg daily + sotalol
Trial: 2865914
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl (50 μg)
Trial: 18093108
Drug: High medication
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High medication guideline adherence
Trial: 16239318
Drug: Flu‐Met plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flu‐Met plus oral contraceptive
Trial: 16239318
Drug: Flu‐Met plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flu‐Met plus transdermal contraceptive
Trial: 12672915
Drug: Egg (640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egg (640 mg/d additional dietary cholesterol)
Trial: 12672915
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg/d additional dietary cholesterol)
Trial: 3946247
Drug: pindolol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol (10 or 20 mg daily) and hydrochlorothiazide (50 mg daily)
Trial: 30497467
Drug: Methadone Maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone Maintenance Treatment Programme (MMTP)
Trial: 26731696
Drug: Norfloxacin 800
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin 800 mg/day for 10 days
Trial: 20942646
Drug: RG7128 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7128 monotherapy for 2 weeks (1500 mg twice daily)
Trial: 20942646
Drug: RG7128 in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7128 in combination with SOC for 4 weeks (1000 mg and 1500 mg twice daily)
Trial: 18806709
Drug: Probiotics (PBs)
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (PBs) administration
Trial: 14558182
Drug: Medication advice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication advice and reviews by specialists in clinical pharmacology and cardiology.
Trial: 10906167
Drug: Internal medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal medicine service (n = 105)
Trial: 10906167
Drug: Internal medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal medicine service
Trial: 2566321
Drug: Celiprolol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (400 mg)
Trial: 31126278
Drug: ACTI-BREAK intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ACTI-BREAK intervention (3 x 5-minute moderate-intensity breaks daily)
Trial: 20632097
Drug: Live View
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live View Video Capsule Endoscopy (VCE)
Trial: 19056590
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g whole egg protein
Trial: 19056590
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g whole egg protein
Trial: 19056590
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g whole egg protein
Trial: 19056590
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g whole egg protein
Trial: 19056590
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g whole egg protein
Trial: 11799544
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy and physician advice
Trial: 7756587
Drug: Cytotoxic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytotoxic agents (cyclophosphamide or chlorambucil)
Trial: 7756587
Drug: Symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic treatment or corticosteroids (control group)
Trial: 2111195
Drug: Nitrogen intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen intake of 0.2 g kg body-weight-1 24 h-1
Trial: 2111195
Drug: Nitrogen intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen intake of 0.3 g kg body-weight-1 24 h-1
Trial: 2111195
Drug: Nitrogen intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen intake of 0.1 g kg body-weight-1 24 h-1
Trial: 2111195
Drug: Nitrogen intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrogen intake of 0.0 g kg body-weight-1 24 h-1
Trial: 761953
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg nomifensine
Trial: 761953
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg racemic amphetamine
Trial: 30964707
Drug: Rosiglitazone (PPARγ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (PPARγ agonist)
Trial: 6126901
Drug: Haloperidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (1 mg)
Trial: 16516824
Drug: Chlorpromazine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (10 mg)
Trial: 16516824
Drug: Nalbuphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (5 mg, intravenous)
Trial: 16516824
Drug: Nalbuphine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine (5 mg, intravenous) with neuroleptics
Trial: 10740150
Drug: Intravenous felodipine
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous felodipine 0.3 mg
Trial: 10740150
Drug: Oral felodipine
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral felodipine 10 mg
Trial: 2006757
Drug: bezafibrate 400
RxNorm normalized name: bezafibrate 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate 400 mg/day
Trial: 2006757
Drug: simvastatin 10-40
RxNorm normalized name: ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: simvastatin 10-40 mg/day
Trial: 6128281
Drug: Tiopronin 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiopronin 600 mg daily
Trial: 29414980
Drug: Pre-treatment costs
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment costs incurred by patients
Trial: 29414980
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to treatment initiation
Trial: 27168361
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg V116517
Trial: 27168361
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg celecoxib
Trial: 12111113
Drug: Oral topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral topotecan (2.3 mg/m(2))
Trial: 12111113
Drug: Intravenous topotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous topotecan (1.5 mg/m(2))
Trial: 6627825
Drug: Gentamicin (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (1.7 mg/kg as a 20‐min infusion every 8 hr for 10 days)
Trial: 6627825
Drug: Netilmicin (1.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netilmicin (1.7 mg/kg as a 20‐min infusion every 8 hr for 10 days)
Trial: 29671128
Drug: Intranasal doxylamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal doxylamine succinate 3.2 mg
Trial: 29671128
Drug: Intranasal doxylamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal doxylamine succinate 6.3 mg
Trial: 29671128
Drug: Intranasal doxylamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal doxylamine succinate 12.7 mg
Trial: 29671128
Drug: Doxylamine succinate
RxNorm normalized name: Doxylamine Succinate
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxylamine succinate 25 mg oral tablet
Trial: 29671128
Drug: Intranasal doxylamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal doxylamine (all doses)
Trial: 25199696
Drug: Epidural injection
RxNorm normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injection of dexamethasone (2 mL, 8 mg)
Trial: 19912273
Drug: Immediate implant
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implant placement into extraction sockets
Trial: 18331601
Drug: CHOP (doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP (doxorubicin 50 mg/m2)
Trial: 18331601
Drug: CNOP (mitoxantrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNOP (mitoxantrone 10-12 mg/m2)
Trial: 14634144
Drug: Oral estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estriol treatment
Trial: 10680109
Drug: Epidural ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural ketamine (0.2 mg/kg)
Trial: 10680109
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (2 mg epidural morphine)
Trial: 1768504
Drug: All three
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All three agents (D, M, S)
Trial: 31845587
Drug: Valproate with
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate with 24 weeks of atypical antipsychotic
Trial: 31845587
Drug: Lithium with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium with 24 weeks of atypical antipsychotic
Trial: 31499383
Drug: Dexamethasone 10
RxNorm normalized name: dexamethasone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg/m2/d for 14 days
Trial: 31499383
Drug: Dexamethasone 6
RxNorm normalized name: dexamethasone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 6 mg/m2/d for 28 days (standard dosing)
Trial: 27063678
Drug: Volunteer support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteer support for self-managed computerised aphasia treatment
Trial: 9588664
Drug: Trimetazidine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (60 mg orally)